1. Figure 4 Effect of dapagliflozin on HbA1c and body weight
Figure 4 | Effect of dapagliflozin on HbA1c and body weight. a | In patients with type 2 diabetes mellitus (T2DM) the initial decline (0–6 months) in HbA1c is more rapid and greater with glipizide than with dapagliflozin. After 6 months, however, HbA1c rises progressively in glipizide-treated patients and after 12 months the reduction in HbA1c is significantly greater with dapagliflozin than with glipizide. b | Glipizide therapy in patients with T2DM is associated with significant weight gain. In contrast, dapagliflozin therapy was associated with a weight loss of 3–4 kg over 208 weeks. Of note, dapagliflozin-treated patients maintained their weight loss over the 4 year duration of the study., S. et al. Long-term glycaemic response and tolerability of dapagliflozin versus a sulfonylurea as add-on therapy to metformin in patients with type 2 diabeteModified with permission from Del Pratos: 4-year data. Diabetes Obes. Metab. 17, 581–590 (2015).
Modified with permission from Del Prato, S. et al. Long-term glycaemic response and tolerability
of dapagliflozin versus a sulfonylurea as add‑on therapy to metformin in patients with type
2 diabetes: 4‑year data. Diabetes Obes. Metab. 17, 581–590 (2015)
DeFronzo, R. A. et al. (2016) Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
Nat. Rev. Nephrol. doi: /nrneph